Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : IL0006290147
Compare
Compare
Traded in other countries / regions
TEVA.IsraelTEVA.USA0LER.UKTEV.GermanyTEVA.MexicoTEVA.AustriaT1EV34.BrazilTEV.Bulgaria IPO Date
1961-01-01Description
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.15 | |||||
| Debt-to-Equity | 3.18 | |||||
| Debt-to-EBITDA | 12.77 | |||||
| Interest Coverage | 3.79 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 0.32 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.4 | |||||
| 3-Year EPS without NRI Growth Rate | -0.1 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -9.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 4.94 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.19 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.25 | |||||
| 9-Day RSI | 83.37 | |||||
| 14-Day RSI | 77.73 | |||||
| 6-1 Month Momentum % | -0.27 | |||||
| 12-1 Month Momentum % | 65.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.89 | |||||
| Quick Ratio | 0.61 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 172.73 | |||||
| Days Sales Outstanding | 76.07 | |||||
| Days Payable | 104.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | 5.62 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.84 | |||||
| Operating Margin % | 22.23 | |||||
| Net Margin % | -5.72 | |||||
| FCF Margin % | 8.16 | |||||
| ROE % | -14.05 | |||||
| ROA % | -2.27 | |||||
| ROIC % | 22.62 | |||||
| ROC (Joel Greenblatt) % | 7.54 | |||||
| ROCE % | 1.54 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.01 | |||||
| PE Ratio without NRI | 7.97 | |||||
| PS Ratio | 1.48 | |||||
| PB Ratio | 4.12 | |||||
| Price-to-Free-Cash-Flow | 18.19 | |||||
| Price-to-Operating-Cash-Flow | 13.36 | |||||
| EV-to-EBIT | 90.38 | |||||
| EV-to-Forward-EBIT | 13.92 | |||||
| EV-to-EBITDA | 27.17 | |||||
| EV-to-Forward-EBITDA | 10.25 | |||||
| EV-to-Revenue | 2.45 | |||||
| EV-to-Forward-Revenue | 2.37 | |||||
| EV-to-FCF | 29.93 | |||||
| Price-to-Projected-FCF | 2.34 | |||||
| Price-to-Median-PS-Value | 1.88 | |||||
| Earnings Yield (Greenblatt) % | 1.1 | |||||
| FCF Yield % | 5.45 | |||||
| Forward Rate of Return (Yacktman) % | 10.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₪) | 61,191.09 | ||
| EPS (TTM) (₪) | -3.101 | ||
| Beta | 0 | ||
| Volatility % | 27.52 | ||
| 14-Day RSI | 77.73 | ||
| 14-Day ATR (₪) | 2.690079 | ||
| 20-Day SMA (₪) | 64.3545 | ||
| 12-1 Month Momentum % | 65.62 | ||
| 52-Week Range (₪) | 37.5 - 80.8 | ||
| Shares Outstanding (Mil) | 1,133.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Teva Pharmaceutical Industries Ltd Stock Events
| Event | Date | Price(₪) | ||
|---|---|---|---|---|
| No Event Data | ||||
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(XTAE:TEVA)'s stock price today?
The current price of XTAE:TEVA is ₪79.69. The 52 week high of XTAE:TEVA is ₪80.80 and 52 week low is ₪37.50.
When is next earnings date of Teva Pharmaceutical Industries Ltd(XTAE:TEVA)?
The next earnings date of Teva Pharmaceutical Industries Ltd(XTAE:TEVA) is 2025-01-29.
Does Teva Pharmaceutical Industries Ltd(XTAE:TEVA) pay dividends? If so, how much?
Teva Pharmaceutical Industries Ltd(XTAE:TEVA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers